Letter from the editor.
Chief Technology Officer; FutuRx, Ltd.; Ness Ziona, Israel.
Ronald
R
Ellis
Acquisitions Editor; Landes Bioscience; Vienna, Austria.
Eva M
EM
Riedmann
D001424:Bacterial Infections / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017048:Health Care Costs; D006801:Humans; D012555:Schistosomiasis mansoni / Q000453:epidemiology / Q000517:prevention & control*; D013678:Technology, Pharmaceutical; D014611:Vaccination / Q000379:methods* / Q000706:statistics & numerical data; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D014777:Virus Diseases / Q000453:epidemiology / Q000517:prevention & control*
D014612:Vaccines